Efficacy and safety of novel probiotics in Vietnamese patients with irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003831

Enrollment

Registered

2019-04-23

Start date

2018-10-10

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : The random allocation sequence was conducted using a computer-generated, blocked randomization list independent of the research group and with a concealed block. During the interv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The Vietnamese living in Korea aged between 19 and 75 years who met the ROME III criteria (symptoms being present for > 6 months and at least three days a month in the past three months)1 for the diagnosis of IBS were eligible to participate.

Exclusion criteria

Exclusion criteria: The exclusion criteria were previous abdominal surgery except appendectomy and Caesarian section, inflammatory bowel syndrome, and concurrent severe illness (cancer, cardiovascular or pulmonary disease). In addition, patients who had used antipsychotics and probiotics within the two weeks were also excluded.

Design outcomes

Primary

Measure	Time frame
Subject global assessment	—

Secondary

Measure	Time frame
VAS score	—

Countries

Korea, Republic of

Contacts

Public ContactYANG WON MIN

Samsung Medical Center

yangwonee@gmail.com+82-2-3410-3409

Outcome results